7 Result(s)

Article

Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer

Mutations in genes for hereditary non-polyposis colorectal cancer (HNPCC) in ovarian cancer patients remains poorly defined. We sought to estimate the frequency and characteristics of HNPCC gene mutations in a...

T Pal, M R Akbari, P Sun, J-H Lee, J Fulp, Z Thompson… in British Journal of Cancer (2012)

Article

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study

Folate receptor 1 (FOLR1) is expressed in the majority of ovarian carcinomas (OvCa), making it an attractive target for therapy. However, clinical trials testing anti-FOLR1 therapies in OvCa show mixed results...

M Köbel, J Madore, S J Ramus, B A Clarke, P D P Pharoah… in British Journal of Cancer (2014)

Article

Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium

Aberrant Wnt signaling within breast cancer is associated with poor prognosis, but regulation of this pathway in breast tissue remains poorly understood and the consequences of immediate or long-term dysregula...

C S Daly, P Shaw, L D Ordonez, G T Williams, J Quist, A Grigoriadis, J H Van Es… in Oncogene (2017)

Article

Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation

Acute Graft versus Host Disease (aGvHD) grades 2–4 occurs in 15–60% of pediatric patients undergoing allogeneic haematopoietic stem-cell transplantation (allo-HSCT). The collateral damage to normal tissue by c...

C. R. S. Uppugunduri, P. Huezo-Diaz Curtis, T. Nava… in The Pharmacogenomics Journal (2022)

Article

CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method

Berzosertib (M6620) is a highly potent (IC50  =  19 nM) and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. This trial assessed the safety, preliminary ...

S. R. Javed, S. Lord, S. El Badri, R. Harman, J. Holmes… in British Journal of Cancer (2024)

Article

Correction: Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium

C. S. Daly, P. Shaw, L. D. Ordonez, G. T. Williams, J. Quist, A. Grigoriadis… in Oncogene (2024)